U.S. markets open in 8 hours 17 minutes
  • S&P Futures

    4,631.75
    -23.00 (-0.49%)
     
  • Dow Futures

    35,728.00
    -68.00 (-0.19%)
     
  • Nasdaq Futures

    15,425.25
    -170.50 (-1.09%)
     
  • Russell 2000 Futures

    2,149.80
    -7.90 (-0.37%)
     
  • Crude Oil

    85.13
    +1.31 (+1.56%)
     
  • Gold

    1,814.60
    -1.90 (-0.10%)
     
  • Silver

    22.93
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1399
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    1.7720
    0.0000 (0.00%)
     
  • Vix

    19.19
    -1.12 (-5.51%)
     
  • GBP/USD

    1.3639
    -0.0008 (-0.06%)
     
  • USD/JPY

    114.8330
    +0.2530 (+0.22%)
     
  • BTC-USD

    42,197.79
    -517.56 (-1.21%)
     
  • CMC Crypto 200

    1,011.26
    -14.47 (-1.41%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,280.62
    -52.90 (-0.19%)
     

Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DURHAM, N.C., September 07, 2021--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will participate in the following virtual investor conferences.

  • Citi 16th Annual BioPharma Conference

    • Date: Thursday, September 9, 2021

    • Time: 8:50 a.m. Eastern Time

    • Panel Discussion: Eyes on the Prize – Next Generation Retinal Therapeutics

  • Wells Fargo Healthcare Conference

    • Date: Friday, September 10, 2021

    • Time: 8:40 a.m. Eastern Time

    • Presentation Type: Fireside

The panel and fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005024/en/

Contacts

Ami Bavishi 908-947-3949; abavishi@aeriepharma.com